European Journal of Pediatrics

, Volume 144, Issue 2, pp 191–194 | Cite as

Anticoagulant therapy by continuous heparin-abtithrombin III infusion in newborns with disseminated intravascular coagulation

  • R. von Kries
  • H. Stannigel
  • U. Göbel
Original Investigations


In ten newborns with severe alteration of the coagulation system due to DIC, AT III concentrate was infused continuously after prior activation with heparin. The rise in AT III activity showed a great variability among the infants and for one child during the course of the therapy. The mean rise of AT III activity by 40 U/kg per day heparin was 8.7%. If AT III concentrate (40 U/kg per day) was activated with 200 U/kg per day heparin, excessive anticoagulatory effect was only observed in one child. In four children who had failed to respond to prior heparin therapy, improvement of the coagulation status was achieved within 2 days.

Key words

Antithrombin III Newborns Disseminated intravascular coagulation Anticoagulant therapy 



disseminated intravascular coagulation


antithrombin III


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blauhut B, Necek S, Kramar H, Vinazzer H, Bergmann H (1980) Activity of antithrombin III and effect of heparin on coagulation in shock. Thromb Res 19:775–782Google Scholar
  2. 2.
    Blauhut B, Necek S, Vinazzer H, Bergmann H (1982) Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 27:271–278Google Scholar
  3. 3.
    Göbel U, von Voss H, Petrich C, Jürgens H, Oliven A (1979) Etiopathology and classification of acquired coagulation disorders in the newborn infant. Klin Wochenschr 57:81–86Google Scholar
  4. 4.
    Göbel U, von Voss H, Jürgens H, Petrich C, Pothmann R, Sprock I, Lemburg P (1980) Efficiency of heparin in the treatment of newborn infants with respiratory distress syndrome and disseminated intravascular coagulation. Eur J Pediatr 133:47–49Google Scholar
  5. 5.
    von Kries R, Jürgens H, Göbel U (1982) Applikation und Dosierung der Antithrombin III-Substitution im Kinderalter. In: van der Loo J, Asbeck F (eds) Hämostase, Thrombophilie und Arteriosklerose. Schattauer Verlag, Stuttgart New YorkGoogle Scholar
  6. 6.
    Markarian M, Lubchenko LO, Rosenblüt E, Fernandez F, Lang D, Jackson JJ, Bannon AE, Lindley A, Githens JH, Martorell R (1971) Hypercoagulability in premature infants with special reference to the respiratory distress syndrome and hemorrhage. II. Effect of heparin. Biol Neonate 17:98–111Google Scholar
  7. 7.
    McDonald M, Hathaway E (1984) Anticoagulant therapy by continuous heparinization in newborn and older infants. J Pediatr 101:451–457Google Scholar
  8. 8.
    Schipper H, Jenkins C, Kahle L, Ten Cate J (1978) Antithrombin-III-transfusion in disseminated intravascular coagulation. Lancet I:845–856Google Scholar
  9. 9.
    Schmidt B, Wais U, Pringsheim W, Künzer W (1984) Plasma elimination of antithrombin III (heparin cofactor activity) is accelerated in term newborn infants. Eur J Pediatr 141:225–227Google Scholar
  10. 10.
    Teger-Nilsson A (1975) Antithrombin in infancy and childhood. Acta Pediatr Scand 64:624–628Google Scholar
  11. 11.
    Thaler E, Lechner K (1982) Substitutionstherapie mit Antithrombin-III-Konzentrat. Dtsch Med Wochenschr 107:147–149Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • R. von Kries
    • 1
  • H. Stannigel
    • 1
  • U. Göbel
    • 2
  1. 1.Abteilung für Neonatologie und GastroenterologieZentrum für Kinderheilkunde der Universität DüsseldorfFederal Republic of Germany
  2. 2.Abteilung für Pädiatrische Hämatologie und OnkologieZentrum für Kinderheilkunde der Universität DüsseldorfFederal Republic of Germany

Personalised recommendations